Chief Scientific Officer & Regulatory Affairs, Tetra Bio-Pharma
Dr. Guy Chamberland, M.Sc., Ph.D., M.H., has been Chief Scientific Officer and Regulatory Affairs of Tetra Bio-Pharma since June 2016. He has over 23 years’ experience in the development of new drugs in the pharmaceutical industry (in both Canada and the U.S.). He developed a specialty in regulatory affairs including drugs, biologics, medical device, combination products and botanicals, and was the Program Director of MDS Pharma Services. Dr. Chamberland has over 10 years experience in the development of clinical research protocols for botanical medicines and the management of these clinical studies in the areas of anxiety, sleep, pain, depression, inflammation and wound healing. He served as Vice President of Clinical and Regulatory Affairs at Victhom Laboratory Inc. from 2005 to 2007 and was Vice President of Regulatory Affairs and Product Development at Biotanika Health Group Inc. from 2007 - 2008. He works closely with physicians and naturopathic physicians in these clinical areas. He spent six years as the Co-Chair and member of Health Canada's Expert Advisory Committee for Veterinary Natural Health Products and Low Risk VHP. He was a member of the Investment Committee of Fonds Bionovation for seven years. Since 2007, Dr. Chamberland has developed an expertise in the development of botanical medicines including cannabis-based prescription drugs.